Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

Citation
Coates, A. S., E. P. Winer, A. Goldhirsch, R. D. Gelber, M. Gnant, M. Piccart-Gebhart, B. Thürlimann, and H.-J. Senn. 2015. “Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.” Annals of Oncology 26 (8): 1533-1546. doi:10.1093/annonc/mdv221. http://dx.doi.org/10.1093/annonc/mdv221.

Published Version
doi:10.1093/annonc/mdv221

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:17820849

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

A. S. Coates¹, E. P. Winer², A. Goldhirsch³*, R. D. Gelber⁴, M. Gnant⁵, M. Piccart-Gebhart⁶, B. Thürlimann⁷, H.-J. Senn⁸ & Panel Members†

¹International Breast Cancer Study Group, University of Sydney, Sydney, Australia; ²Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA; ³International Breast Cancer Study Group, Program of Breast Health (Senology), European Institute of Oncology, Milan, Italy; ⁴International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA; ⁵Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; ⁶Internal Medicine/Oncology, Institut Jules Bordet, Brussels, Belgium; ⁷Breast Center, Kantonsspital St Gallen, St Gallen; ⁸Tumor and Breast Center ZeTuP, St Gallen, Switzerland

Received 27 April 2015; accepted 28 April 2015

The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as ‘no ink on invasive tumor or DCIS’ and the safety of omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation of regional nodes in node-positive disease. Considering subdivisions within luminal disease, the Panel was more concerned with indications for the use of specific therapies, rather than surrogate identification of intrinsic subtypes as measured by multiparameter molecular tests. For the treatment of HER2-positive disease in patients with node-negative cancers up to 1 cm, the Panel endorsed a simplified regimen comprising paclitaxel and trastuzumab without anthracycline as adjuvant therapy. For premenopausal patients with endocrine responsive disease, the Panel endorsed the role of ovarian function suppression with either tamoxifen or exemestane for patients at higher risk. The Panel noted the value of an LHRH agonist given during chemotherapy for premenopausal women with ER-negative disease in protecting against premature ovarian failure and preserving fertility. The Panel noted increasing evidence for the prognostic value of commonly used multiparameter molecular markers, some of which also carried prognostic information for late relapse. The Panel noted that the results of such tests, where available, were frequently used to assist decisions about the inclusion of cytotoxic chemotherapy in the treatment of patients with luminal disease, but noted that threshold values had not been established for this purpose for any of these tests. Multiparameter molecular assays are expensive and therefore unavailable in much of the world. The majority of new breast cancer cases and breast cancer deaths now occur in less developed regions of the world. In these areas, less expensive pathology tests may provide valuable information. The Panel recommendations on treatment are not intended to apply to all patients, but rather to establish norms appropriate for the majority. Again, economic considerations may require that less expensive and only marginally less effective therapies may be necessary in less resourced areas. Panel recommendations do not imply unanimous agreement among Panel members. Indeed, very few of the 200 questions received 100% agreement from the Panel. In the text below, wording is intended to convey the strength of Panel support for each recommendation, while details of Panel voting on each question are available in supplementary Appendix S2, available at Annals of Oncology online.

**Key words:** surgery, radiation therapy, systemic adjuvant therapies, early breast cancer, St Gallen Consensus

---

© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
light of the most recent and reliable information from clinical trials, laboratory insights and the expert opinions of a large international faculty. To this end, attention is given to tumor factors and the condition of the host. Tumor factors are primarily the presence or absence of targetable features such as hormone receptors and HER2, and the metastatic potential, as reflected in measures of proliferation and anatomic extent of disease. Patient factors include menopausal status, age, comorbidity, and patient preference.

**St Gallen 2015: news and progress**

A large part of the world has an increasing incidence of breast cancer, but limited resources to treat it. The majority of new cases and the majority of breast cancer deaths now occur in less developed regions of the world [1]. Many of the countries in the less developed regions have low health expenditure per capita, which renders the use of expensive laboratory tests and treatments inaccessible to the majority of patients worldwide (http://data.worldbank.org/indicator/SH.XPD.PCAP?display=map accessed 29.12.2014). The development of effective treatments which are less expensive is thus a priority [2].

The Panel welcomed a number of recent clinical trial results, especially the SOFT and TEXT trials clarifying the role of ovarian function suppression with tamoxifen or exemestane in the endocrine treatment of premenopausal patients, and the POEMS trial confirming the protective value of an LHRH agonist for ovarian function [3-5]. A curious paradox emerged in the evidence for local therapies. Surgical management continued its trend to less extensive surgery without compromise of the outcome [6,7], but recent radiotherapy trials in node-positive disease found superior disease control with extended radiation fields which included regional lymph node areas [8,9]. No such benefit was seen in a population-based study [10]. Hypofractionated shorter course radiotherapy has become accepted as a standard option [11,12] offering increased patient convenience and reduced resource usage.

A recent update of the overview of adjuvant aromatase inhibitors (AIs) (Dowsett M, personal communication) in postmenopausal patients found that, on average, patients have fewer recurrences while assigned AI than while assigned tamoxifen during those periods when the treatments differed, although there was no significant difference in breast cancer mortality in trials comparing 5 years of an AI to the sequence of tamoxifen followed by an AI.

**Breast cancer subtypes**

Extensive genomic analysis of breast cancers discloses four coherent groups [13], similar to the intrinsic subtypes defined by gene expression profiling [14]. Subtypes can be defined by multiparameter molecular tests such as the PAM-50 [15] or MammaPrint/BluePrint [16]. However, in clinical practice, the key question is not the separation of the molecularly defined intrinsic subtypes, but the discrimination between patients who will or will not benefit from particular therapies. Several of the multiparameter molecular markers have been used for this purpose [17,18]. Because in much of the world, such tests may not be available for logistic or financial reasons, surrogate approaches have been developed using more widely available immunohistochemical (IHC) tests for estrogen receptor, progesterone receptor together with IHC or in situ hybridization tests for HER2 overexpression or amplification. Ki-67 is used as an alternative marker of proliferation albeit with lesser analytical validity than molecular testing [19,20].

Standard pathological features seem adequate to define clinically useful groups such as triple-negative, hormone receptor-negative and HER2-positive and hormone receptor-positive and HER2-positive tumors for which treatment recommendations are seldom controversial. It is among the patients with 'luminal' disease, defined by the presence of ER and/or PgR and negative HER2, that uncertainty about optimal treatment most commonly arises, as clinicians seek to avoid overtreatment and undertreatment. A survey of patterns of the use of chemotherapy in such patients [21,22] showed that there was a substantially different use of chemotherapy in different geographical areas.

The various multiparameter molecular marker assays all include genes reflecting proliferative activity: indeed, it has been suggested that the majority of the prognostic information in these tests comes from the proliferative genes included [23]. IHC measurement of proliferative activity using the Ki-67 assay has proved controversial. There can be little doubt that Ki-67 scores carry robust prognostic information [24], and that high values predict the benefit of addition of cytotoxic chemotherapy [25], but definition of a single useful cut point has proved elusive both because Ki-67 displays a continuous distribution [26], and as a result of analytic and preanalytic barriers to standardized assessment [27]. Other news presented at the meeting is summarized in Table 1.

**Panel deliberations**

On the Saturday morning, the Panel reviewed a series of some 200 questions developed by iterative consultation over the months preceding the conference. Voting on most questions was in the format yes, no, or abstain, with some presented as multiple mutually exclusive alternatives. Abstaining was recommended if a Panel member had a conflict of interest, felt that there was insufficient evidence to support an opinion or that he or she lacked the relevant expertise. Detailed voting records for each of the questions put to the Panel are provided in the supplementary Appendix S2, available at Annals of Oncology online.

**Surgery of the primary**

The Panel strongly endorsed recent findings that the minimal acceptable surgical margin was ‘no ink on invasive tumor or DCIS’. This conclusion applies regardless of tumor characteristics such as lobular histology, extensive intraductal component, young age, multifocality or multicentricity, and unfavorable biological subtype [7].

A clear majority of the Panel agreed that multifocal and multicentric tumors could be treated with breast conservation, provided the above margin clearance was obtained and whole-breast radiotherapy was planned.

Following neoadjuvant chemotherapy, the Panel did not consider it necessary to resect the entire area of the original primary if downstaging had occurred.
Cancer genomics

Multiple recent studies have described the landscape of the expanding list of mutations and other genetic abnormalities in patients with recurrent breast cancer. Apart from a small number of cases, these differences are infrequent but may cluster in particular pathways such as the JUN kinase pathway [41].

Avoiding axillary dissection for patients with one or two macrometastatic lymph nodes [30, 31] proved safe in a large institutional series, confirming the applicability of randomized trial approaches (ACOSOG Z011, AMAROS) for the majority of women with T1 and T2 clinically node-negative breast cancer [6].

Extent of locoregional radiotherapy

Two recent radiotherapy trials in node-positive disease found superior disease control with extended radiation fields which included regional lymph node areas [8, 9].

Prognostic value of multiparameter molecular markers

Oncotype DX® was predictive of late distant recurrence in NSABP B-14 [32]. However, it was not predictive of late distant recurrence after endocrine therapy in the ATAC study, while PAM-50 ROR score® [17, 33] and the immunohistochemically based IHC4® each remained prognostically significant beyond 5 years of endocrine treatment [34, 35]. Likewise, EndoPredict® was prognostically significant beyond 5 years in ABCSG trials 6 and 8, particularly when combined with clinical factors [36]. Breast Cancer Index® was prognostic for early and late distant recurrence in two series [37].

Reducing the risk of chemotherapy-induced premature ovarian failure

In the recently reported POEMS study [5], OFS with LHRH analogue during chemotherapy for patients with receptor-negative breast cancer reduced the incidence of premature ovarian failure, confirming the report of Del Mastro et al. [38], but contrary to the findings of the ZORO study of the German Breast Group [39]. In the POEMS study, such treatment also increased the rate of subsequent successful pregnancies and did not compromise disease outcomes [5].

Observational registry data

Because only a small fraction of patients are entered on randomized clinical trials, evolving standardized registry datasets offer information which may be more typical of the entire patient population. Although biases can never be entirely removed from such datasets, useful information has been described in many clinical settings including oncology [40].

Cancer genomics

Multiple recent studies have described the landscape of the expanding list of mutations and other genetic abnormalities in patients with recurrent breast cancer. Apart from a small number of cases, these differences are infrequent but may cluster in particular pathways such as the JUN kinase pathway [41].

Genomic tools for marker assessment

Genomic tests added little to IHC for the assessment of ER and only slightly more for PgR, while there was more substantial disagreement between conventional and genomic testing for HER2 [42, 43].

Intrinsic subtypes

Attempts to reproduce the intrinsic subtype distinction between 'luminal A-like' and 'luminal B-like' using conventional pathology have proved impractical. While it is possible to refine definitions to more closely approximate intrinsic subtypes [19, 44, 45], this may not provide the clinically useful threshold to guide treatment choice.

Intrinsic subtypes within HER2-positive disease are heterogeneous and, in one study, this was reflected in potential differences in predicting degree of response to trastuzumab [46]. The difference between the hormone receptor-negative and positive cohorts within HER2-positive disease is illustrated by the consistently higher clinical response (pCR) to neoadjuvant therapies for the hormone receptor-negative cohort [47, 48].

Although a majority of triple-negative breast cancers show the basal-like subtype [49], the distinction between these and other types of triple-negative breast cancer is important for choice of chemotherapy in that carboplatin is as effective as docetaxel in basal-like but less so in other intrinsic subtypes in the metastatic setting [50]. Further dissection of subtypes within triple-negative breast cancer reveals seven distinct groupings, which differ markedly in their clinical response to neoadjuvant chemotherapy [51]. Preclinical studies also show heterogeneity of response to other agents in cell lines of the different triple-negative subtypes [52], though this subclassification is not yet ready for clinical application.

Tumour-infiltrating lymphocytes (TILs)

TILs are most often found in triple-negative (TN), HER2-positive, and other highly proliferative breast cancers, and have been associated with increased pCR, longer disease-free survival (DFS), and improved overall survival (OS), independent of other prognostic factors [53, 54] in some studies, though not among patients treated with trastuzumab in the N9831 trial [55].

Table 1. Recent research findings presented at the 14th International Conference on Primary Therapy of Early Breast Cancer and their implications for patient care

| Field or treatment | Status of research/implications for patient care |
|--------------------|--------------------------------------------------|
| Surgical management | Local regional recurrence is becoming less frequent over recent decades [28]. Meta-analysis of surgical series showed no further benefit from margins beyond 'no ink on invasive tumor or DCIS' [29]. This conclusion applies regardless of tumor characteristics such as lobular histology, extensive intraductal component, young age, and unfavorable biological subtype [7]. Avoiding axillary dissection for patients with one or two macrometastatic lymph nodes [30, 31] proved safe in a large institutional series, confirming the applicability of randomized trial approaches (ACOSOG Z011, AMAROS) for the majority of women with T1 and T2 clinically node-negative breast cancer [6]. |
| Extent of locoregional radiotherapy | Two recent radiotherapy trials in node-positive disease found superior disease control with extended radiation fields which included regional lymph node areas [8, 9]. |
| Prognostic value of multiparameter molecular markers | Oncotype DX® was predictive of late distant recurrence in NSABP B-14 [32]. However, it was not predictive of late distant recurrence after endocrine therapy in the ATAC study, while PAM-50 ROR score® [17, 33] and the immunohistochemically based IHC4® each remained prognostically significant beyond 5 years of endocrine treatment [34, 35]. Likewise, EndoPredict® was prognostically significant beyond 5 years in ABCSG trials 6 and 8, particularly when combined with clinical factors [36]. Breast Cancer Index® was prognostic for early and late distant recurrence in two series [37]. |
| Reducing the risk of chemotherapy-induced premature ovarian failure | In the recently reported POEMS study [5], OFS with LHRH analogue during chemotherapy for patients with receptor-negative breast cancer reduced the incidence of premature ovarian failure, confirming the report of Del Mastro et al. [38], but contrary to the findings of the ZORO study of the German Breast Group [39]. In the POEMS study, such treatment also increased the rate of subsequent successful pregnancies and did not compromise disease outcomes [5]. |
| Observational registry data | Because only a small fraction of patients are entered on randomized clinical trials, evolving standardized registry datasets offer information which may be more typical of the entire patient population. Although biases can never be entirely removed from such datasets, useful information has been described in many clinical settings including oncology [40]. |
| Cancer genomics | Multiple recent studies have described the landscape of the expanding list of mutations and other genetic abnormalities in patients with recurrent breast cancer. Apart from a small number of frequently mutated genes, there is a long 'tail' of genetic abnormalities, which are infrequent but may cluster in particular pathways such as the JUN kinase pathway [41]. |
| Genomic tools for marker assessment | Genomic tests added little to IHC for the assessment of ER and only slightly more for PgR, while there was more substantial disagreement between conventional and genomic testing for HER2 [42, 43]. |
| Intrinsic subtypes | Attempts to reproduce the intrinsic subtype distinction between 'luminal A-like' and 'luminal B-like' using conventional pathology have proved impractical. While it is possible to refine definitions to more closely approximate intrinsic subtypes [19, 44, 45], this may not provide the clinically useful threshold to guide treatment choice. |
| Intrinsic subtypes within HER2-positive disease are heterogeneous and, in one study, this was reflected in potential differences in predicting degree of response to trastuzumab [46]. The difference between the hormone receptor-negative and positive cohorts within HER2-positive disease is illustrated by the consistently higher clinical response (pCR) to neoadjuvant therapies for the hormone receptor-negative cohort [47, 48]. |
| Although a majority of triple-negative breast cancers show the basal-like subtype [49], the distinction between these and other types of triple-negative breast cancer is important for choice of chemotherapy in that carboplatin is as effective as docetaxel in basal-like but less so in other intrinsic subtypes in the metastatic setting [50]. Further dissection of subtypes within triple-negative breast cancer reveals seven distinct groupings, which differ markedly in their clinical response to neoadjuvant chemotherapy [51]. Preclinical studies also show heterogeneity of response to other agents in cell lines of the different triple-negative subtypes [52], though this subclassification is not yet ready for clinical application. |
| Tumour-infiltrating lymphocytes (TILs) | TILs are most often found in triple-negative (TN), HER2-positive, and other highly proliferative breast cancers, and have been associated with increased pCR, longer disease-free survival (DFS), and improved overall survival (OS), independent of other prognostic factors [53, 54] in some studies, though not among patients treated with trastuzumab in the N9831 trial [55]. |
| Field or treatment                  | Status of research/implications for patient care                                                                                                                                                                                                                                                                                                                                 |
|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-related pathways            | Preclinical studies underline the importance of inflammation and the immune landscape in the stroma, and point to the additional benefit of combining treatments aimed at the immune system (such as anti-IL6) with small molecules such as gefitinib, which inhibit the EGF receptor otherwise enhanced [56]. Immune-targeted drugs may be useful, with recent data available on PD-1 inhibition [57–59]. |
| Targeting CDK 4/6                  | Palbociclib, a CDK 4/6 inhibitor, given with letrozole showed superior clinical efficacy when compared with letrozole alone as first-line treatment in the PALOMA-1/TRIO-18 randomized phase II trial in metastatic breast cancer [60].                                                                                                           |
| Targeting DNA repair pathways      | Patients with deficient DNA repair based on BRCA 1 or BRCA 2 mutation showed high pCR rates to platinum salts [61, 62], and carboplatin is significantly more active than doctaxel in patients with BRCA mutations treated in the metastatic setting [63].                                                                                                   |
| Targeting the PI3K pathway         | The combination of the PIK3CA-alpha-specific inhibitor BYL719 and fulvestrant appears synergistic in preclinical models [64].                                                                                                                                                                                                                                                                                   |
| Targeting the FGFR pathway         | Preliminary studies with the FGFR inhibitors dovitinib [65] and lucitanib [66] show promising response rates but substantial toxicity.                                                                                                                                                                                                                                                                                         |
| Germline genetics                  | In a small observational study, tamoxifen was associated with a reduced risk of contralateral breast cancer in patients with BRCA 1 and BRCA 2 mutations where the index cancer was ER-positive or ER-negative [67].                                                                                                                                                                                                             |
| Primary prevention                 | Recent data have emphasized the role of previous benign pathology with atypia and (although to a lesser extent) even without atypia as a risk factor for breast cancer incidence [68].                                                                                                                                                                                                                                        |
| ER and PgR testing                 | A large single-institution experience suggests that equivocal ER staining between 1% and 9%, more commonly seen among young patients, those with higher grade or HER2-positive or PgR-negative tumors, tracks prognostically more closely with ER absent disease in terms of recurrence-free survival [69]. Since these patients did not receive endocrine therapy, information is not available on the predictive value of these equivocal ER levels. |
| Overcoming endocrine therapy resistance | Combining endocrine agents and blockers of growth factors might be a useful strategy to reverse estrogen receptor-targeted therapy resistance [70].                                                                                                                                                                                                                                         |
| Ki-67 determination                | Extensive studies support the prognostic value of Ki-67, but clinical validation has proved difficult. While high and low values are reproducible and clinically useful, there appears to be no optimal cut point, at least to predict pCR along the continuum of Ki-67 scoring [71, 72]. International collaboration has led to improvements in concordance of the Ki-67 scoring [27, 73]. Image analysis may help to reduce variability [74]. |
| Neoadjuvant systemic therapies     | An improved pCR rate was observed with carboplatin for patients with triple-negative disease [75, 76]. Such improvement was not observed for HER2-positive disease [50, 76]. An improved pCR rate was also observed in triple-negative breast cancer using nab-paclitaxel instead of solvent-based paclitaxel [50]. pCR rates were higher in patients with lymphocyte predominant breast cancer, either triple-negative or HER2-positive, who were treated with carboplatin [77]. PIK3CA mutation was associated with inferior pCR rates to anti-HER2 therapies in several neoadjuvant studies [78–80]. Neoadjuvant endocrine therapies usually take longer to achieve tumor response and pCR rates are generally low. Treatment may continue until maximal response [81]. However, failure to lower Ki-67 offers early identification of a group of patients who should be considered for switch to alternative therapies [82, 83]. Although the neoadjuvant neo-ALTTO trial was clearly positive and supported dual HER2 blockade [84], the adjuvant ALTTO study (using a variety of different chemotherapy regimens) [85] is widely regarded as negative. These apparently conflicting results may not be as divergent as commonly perceived [86]. The hazard ratio in ALTTO of 0.84 comparing dual-blockade with trastuzumab alone [85] was much as expected [86] and the P value of 0.048 is interpreted as nonsignificant because the statistical analysis plan divided alpha between the dual-inhibition comparison and that involving the sequential administration of trastuzumab and lapatinib. |
Table 1. Continued

| Field or treatment | Status of research/implications for patient care |
|--------------------|-------------------------------------------------|
| **Surgery**        | A large US population-based study of more than 200 000 women noted that 7% underwent contralateral prophylactic mastectomy (CPM). Although a small survival benefit was observed [87], information was not available on BRCA status, which is known to be both a motivation for CPM and a marker for increased benefit from such surgery. Thus, selection bias could not be adequately addressed in this registry study [88]. There has been a substantial increase in the use of CPM over the past two decades in the United States, particularly in women <40 [89]. In Europe, the trend is less marked [90, 91]. Sentinel node biopsy is feasible and accurate after neoadjuvant chemotherapy and allows precise assessment of pCR [92–95]. In patients with nodal involvement at presentation, the false-negative rate of sentinel node biopsy is highly correlated with the number of sentinel nodes retrieved. Breast conservation after neoadjuvant chemotherapy is feasible even when the disease is multifocal or multicentric, provided that the margins are free of disease [96]. |
| **Radiation therapy** | Two trials on hypofractionated radiotherapy to the conserved breast examined essentially similar regimens [11, 12]. Hypofractionated regimens involving 15 or 16 fractions are now widely accepted as standard of care [97, 98]. Observational data from a population-based registry suggest that radiotherapy to the internal mammary nodes may be associated with a survival benefit in node-positive breast cancer [99]. |
| **Adjuvant systemic endocrine therapies in premenopausal patients** | For premenopausal women with endocrine responsive disease, results from the SOFT and TEXT trials indicate that the combination of OFS (mainly using triptorelin) and tamoxifen or AI should be considered for women at higher risk of recurrence such as those remaining premenopausal after chemotherapy; those with multiple positive nodes; and those aged under 35 with appropriate disease-associated risks [3, 4]. Given the potential long-term toxicity of OFS and the lack of a demonstrated survival advantage for this strategy to date and indeed an adverse overall survival finding in ABCSG 12 using anastrozole [100], patient preference and treatment tolerance should be strongly considered in initial and subsequent decisions regarding OFS. Patient-reported outcomes in three endocrine therapy studies [101–103] showed distinct and substantial impact on vasomotor, menopausal, and sexual symptoms. There was no difference seen in overall measures of quality of life between the various therapies. A composite risk score was developed for premenopausal patients in the SOFT and TEXT trials and demonstrated that more intensive therapies such as OFS and exemestane were particularly beneficial for patients at higher risk [104]. |
| **Adjuvant systemic endocrine therapies in postmenopausal patients** | In BIG 1–98, the original composite risk score which predicted 5-year DFS [105] was also prognostic for disease outcomes beyond 5 years. Late recurrences did not vary according to treatment allocation during the first 5 years [104]. |
| **Lifestyle and obesity** | Obesity has been associated with poor breast cancer outcomes. The use of anastrozole (but not letrozole) in the adjuvant or extended adjuvant setting may be associated with less benefit in obese women [106]. |
| **Adjuvant systemic cytotoxic chemotherapy** | A study in patients not selected on the basis of hormone receptor, HER2 or menopausal status with 0–3 lymph nodes involved, showed no advantage for six cycles compared with four of the same regimen [107]. A study of bone marrow neoplasms following systemic breast cancer therapy showed a slightly higher incidence (0.4%–0.5% at 10 years) than had previously been appreciated [108]. Neurotoxicity was present at the completion of taxane-based chemotherapy in one-quarter of patients, and one-third of these had persistent symptoms 1–3 years later [109]. The incidence of cardiac toxicity following chemotherapy and anti-HER2 treatment with trastuzumab did not increase with extended follow-up in the HERA trial [110]. |
| **Adjuvant anti-HER2 therapy** | A phase II study of adjuvant paclitaxel and trastuzumab, without anthracycline, showed excellent outcome in node-negative, HER2-positive, pT1b and pT1c tumors. Despite the absence of a control group in this study, the regimen is now widely accepted as a standard of care for patients with small, node-negative, HER2-positive tumors [111]. |
| **Young women** | Age was neither prognostic nor predictive for the impact of trastuzumab in the HERA trial [91]. LHRH agonist therapy during chemotherapy proved effective to protect against premature ovarian failure and preserve fertility in young women with ER-negative breast cancer undergoing chemotherapy [5, 112]. A global observational trial to assess the safety of interrupting endocrine therapy to allow attempted pregnancy is in progress [112]. |
surgery of the axilla
In the light of recent trial results, the Panel considered the situation of patients with macrometastases in one or two sentinel nodes. The Panel was unanimous that following mastectomy such patients required axillary dissection if no radiotherapy were planned, but was almost exactly equally divided if mastectomy were to be followed by radiotherapy. A clear majority of the Panel would accept the omission of axillary dissection following conservative resection with standard tangent radiotherapy planned, and virtually all would do so if the radiotherapy were planned to use high tangents including the lower axilla.

In a patient clinically node positive at presentation who downstages after neoadjuvant chemotherapy, the Panel considered that sentinel node biopsy was appropriate, but that, in this situation, axillary lymph node dissection was required if even one sentinel node were positive. False-negative rates, however, remain high unless three or more sentinel nodes are examined.

radiation therapy
Radiotherapy courses involving hypofractionation were considered appropriate irrespective of age for patients without prior chemotherapy or clinical lymph node involvement. A bare majority of the Panel would accept hypofractionated radiotherapy for patients with axillary lymph node involvement or prior chemotherapy.

Following breast-conserving surgery, the Panel considered that radiation should be limited to breast only if the nodes were negative. The Panel was in favor of at least some regional nodal radiotherapy if the axillary nodes were positive, and a substantial minority would extend this to include the internal mammary nodes [99]. In post-meeting discussions, several Panel members suggested that adverse pathology should identify patients with lower nodal burden requiring radiotherapy.

Following mastectomy, the Panel considered that radiotherapy should be standard for patients with tumor size 5 cm or greater, those with a positive macrometastatic sentinel node biopsy but no axillary dissection, and for patients with one to three involved nodes and adverse pathology. In the absence of adverse pathology, patients with one to three involved nodes could be treated without post mastectomy radiotherapy, though a slim majority would include such treatment of patients aged <40 years. The Panel considered that the same indications for radiotherapy as described above applied after axillary dissection without prior sentinel node biopsy even if less than eight nodes were examined.

If given, the Panel felt that post mastectomy radiotherapy should include the chest wall and regional nodes with most of those voting prepared to omit the internal mammary nodes. After immediate breast reconstruction, the Panel felt that radiotherapy should include the lymph nodes and the reconstructed breast in most cases.

Interestingly, although the Panel did not consider that surgical resection of the original area of tumor was necessary after downstaging with neoadjuvant systemic therapy, they did consider that radiotherapy following neoadjuvant chemotherapy should in general be directed to the extent of disease before such therapy.

pathology
As in previous St Gallen meetings, the Panel was of the strong opinion that the distinction between strongly endocrine responsive, low proliferation, good prognosis ‘luminal A-like’ and less endocrine responsive, higher proliferation, poorer prognosis ‘luminal B-like’ (HER2-negative) tumors could be derived from IHC tests for ER, PgR and Ki-67, though the use of Ki-67 required knowledge of local laboratory values. (The Panel used these terms as a shorthand in classifying hormone receptor-positive disease into luminal A-like and luminal B-like subsets, though it recognized that IHC tests do not accurately measure true intrinsic subtypes.) The corollary was that a clear majority of the Panel did not believe that multiparameter molecular markers were required for this distinction. A majority of the Panel was prepared to accept a threshold value of Ki-67 within the range of 20%–29% to distinguish ‘luminal B-like’ disease, though about one-fifth of the Panel felt that Ki-67 should not be used at all for this distinction. Only a quarter of the Panel believed that subtype determination could be replaced by risk scores derived from multiparameter molecular markers.

A clear majority of the Panel did not accept the presence of tumor-infiltrating lymphocytes (TILs) as either a prognostic or predictive marker.

The Panel considered the role of multiparameter molecular marker assays for prognosis separately in years 1–5 and beyond 5 years, and their value in selecting patients who require chemotherapy. Oncotype DX®, MammaPrint®, PAM-50 ROR® score, EndoPredict®, and the Breast Cancer Index® were all considered usefully prognostic for years 1–5. Beyond 5 years, the Panel was divided almost equally on the prognostic value of Oncotype DX® (despite the available data from NSABP Trial B-14 [32]); EndoPredict® (despite the report of Dubsky et al. [36]); and Breast Cancer Index (despite the report of Zhang et al. [37]). (All these reports show the respective tests to be prognostic beyond 5 years.) PAM50 ROR® score was agreed to be clearly prognostic beyond 5 years, and a clear majority rejected the prognostic value of MammaPrint® in this time period. Only Oncotype DX® commanded a majority in favor of its value in predicting the usefulness of chemotherapy. Clinically, tests which are prognostic, but not specifically predictive of the efficacy of cytotoxic therapy, are commonly used to make decisions about such therapy. This is done on the grounds that they may define a group of patients with a prognosis so good that even if chemotherapy were similarly proportionately effective as in higher risk patients the absolute benefit may be thought insufficient to justify such treatment. Similarly, a test result indicating a worse prognosis may be used to justify the use of effective but more toxic endocrine therapy such as OFS plus AI or more intensive or prolonged chemotherapy.

adjuvant endocrine therapy of premenopausal patients
In the light of recently published results from the SOFT and TEXT trials, the Panel considered treatment recommendations for two clinical scenarios. The first involved a 42-year-old patient with node-negative, grade 2, T1, ER-positive tumor not receiving chemotherapy. A large majority of the Panel would treat such a patient with tamoxifen alone. The second scenario...
involved a 34-year-old patient with lymph node-positive, grade 3, T1, ER-positive disease who remained premenopausal after adjuvant chemotherapy. An overwhelming majority of the Panel would advise OFS for this patient, and a large majority would use this with exemestane rather than tamoxifen.

More generally, the Panel considered that factors arguing for inclusion of OFS were age 35 or less; persistent premenopausal estrogen level after adjuvant chemotherapy; or the involvement of four or more axillary nodes. A lesser majority would add grade 3 disease or an adverse result from a multiparameter molecular marker test as indications for OFS.

Factors arguing for the use of an AI plus OFS rather than tamoxifen plus OFS were (overwhelmingly) the involvement of four or more nodes, with lesser majorities accepting age 35 or less; grade 3; or the adverse result of a multiparameter molecular marker test as supporting such treatment. The Panel was almost evenly divided as to whether a persisting premenopausal estrogen level after adjuvant chemotherapy should favor an AI rather than tamoxifen. As a supplementary question, the Panel was asked, ‘if you decide to give OFS are you more likely to recommend tamoxifen or an AI?’ with a majority favoring AI.

The Panel considered that if OFS were included the optimal duration of such therapy should be 5 years, and that extended endocrine therapy for a total of 10 years should be considered for premenopausal patients initially node-positive or with other adverse pathology.

adjuvant endocrine therapy of postmenopausal patients

The Panel was almost unanimous that some postmenopausal patients can be treated with tamoxifen alone. However, virtually all Panel members regarded the involvement of four or more nodes; grade 3 pathology; or high Ki-67 as arguing for the inclusion of an AI at some point. A lesser majority also felt that HER2 positivity argued in favor of inclusion of an AI, but the Panel did not consider that age <60 should indicate AI therapy. If an AI is used, the Panel was virtually unanimous that it should start up front in patients at higher risk, while the Panel was evenly divided on whether it should be used up front in all patients. The Panel was comfortable to contemplate switching from an AI to tamoxifen after 2 years if necessary.

The Panel was virtually unanimous that following 5 years of adjuvant tamoxifen, patients with initially node-positive disease should continue endocrine therapy to 10 years regardless of menopausal status, but did not consider such extension indicated for initially node-negative disease. A clear majority favored extension to 10 years for patients with grade 3 tumors; high Ki-67; and for patients premenopausal at baseline who became postmenopausal during 5 years of tamoxifen.

The Panel then considered the more complex situation of patients whose initial 5 years of adjuvant therapy had involved a switch from tamoxifen to an AI. A clear majority was in favor of continuing AI therapy to a total cumulative AI duration of 5 years.

Following initial therapy consisting of 5 years of a straight AI, the Panel was evenly divided between recommendations for 3–5 years of tamoxifen; 3–5 more years of an AI; or no further endocrine treatment.

adjuvant cytotoxic chemotherapy

Pending the results of ongoing randomized trials, and notwithstanding the Oxford Overview results [113], the Panel was strongly of the opinion that relative indications for inclusion of adjuvant cytotoxic chemotherapy for patients with ‘luminal’ disease types were grade 3 histology; 4 or more positive nodes; low hormone receptor staining; high Ki-67; and extensive lymphovascular invasion, but the majority did not believe that one to three positive nodes or age <35 were indications for such treatment.

A clear majority of the Panel believed that ‘luminal A-like’ phenotype was less responsive to chemotherapy. They would not add such treatment based on T size; lymphovascular invasion; or the involvement of one to three lymph nodes in such patients. However, the Panel almost unanimously recommended chemotherapy when four or more nodes are involved, presumably since the risk of undertreatment is deemed greater in such patients.

The Panel did not believe that chemotherapy should be recommended in all patients with ‘luminal B-like’ disease. Specifically, it could be omitted in cases with low scores on Oncotype DX®; MammaPrint®; PAM-50 ROR® score; or EndoPredict®. The Panel was evenly divided about whether intermediate Oncotype DX® score should be regarded as an indication for chemotherapy.

When cytotoxic chemotherapy is indicated for luminal disease, the specific choice of regimen depends on the position within the spectrum of degree of endocrine responsiveness and risk of relapse. On average, for ‘luminal B-like’ tumors, the Oxford overview supports the inclusion of both an anthracycline and a taxane [113], while in ‘luminal A-like’ tumors, there is little evidence of an advantage compared with older regimens such as AC and CMF [114]. If given, chemotherapy for ‘luminal B-like’ disease should not extend beyond four courses of the same treatment, especially, for patients with a lower burden of disease. The addition of taxanes should be considered for patients with more extensive disease burden. A slim majority considered that there was a high-risk group for which dose-dense therapy with G-CSF support should be preferred.

In triple-negative disease, the Panel considered that the chemotherapy should include an anthracycline and a taxane. Despite the lack of randomized trial evidence, the Panel would consider a platinum-based regimen in the presence of BRCA mutation, but a large majority felt that standard anthracycline and taxane-based therapy was appropriate for such patients. Platinum-based therapy should not be routinely used in patients without BRCA mutation. The Panel was divided about the value of dose-dense therapy with growth factor support.

In patients with HER2-positive, stage 2 disease, the Panel was almost unanimous that chemotherapy was required and should in general contain an anthracycline and a taxane, with the anti-HER2 therapy starting concurrent with the taxane.

The Panel next considered patients with stage 1, HER2-positive disease. A clear majority felt that anti-HER2 therapy was not required in patients with T1a disease, while a large majority would include such treatment of T1b, and all Panel members would treat patients with T1c disease. A clear majority of the Panel was willing to accept the combination of paclitaxel and trastuzumab without an anthracycline as a reasonable option for stage 1 patients and a maximum tumor diameter of 1 cm thought to require therapy. The Panel was divided about
whether such treatment was appropriate for stage 1 patients with a tumor >1 cm, with a slim majority favoring anthracycline/taxane-based therapy for such patients.

**adjuvant anti-HER2 therapies**

Pending results from the ongoing APHINITY trial, the Panel did not support dual HER2 blockade by the addition of either pertuzumab or lapatinib to trastuzumab for postoperative adjuvant therapy.

**neoadjuvant cytotoxic chemotherapy for luminal disease**

The Panel did not generally support neoadjuvant cytotoxic therapy for patients with 'luminal A-like' tumors, but would contemplate it if conservative surgery would not otherwise be feasible. In patients with 'luminal B-like' (HER2-negative) tumors, the Panel was more closely divided, but only a minority would recommend such treatment for the majority of cases.

**neoadjuvant systemic therapy for stage 2 HER2-positive disease**

The majority of the Panel supported dual anti-HER2 therapy with taxane, trastuzumab, and pertuzumab as 'an acceptable regimen' for such patients.

**neoadjuvant systemic therapy for patients with triple-negative tumours**

The clear majority of the Panel favored anthracycline and taxane-based treatment of such patients, and would not support the use of high-dose alkylating agents or platinums. (The Panel was not asked specifically about neoadjuvant platinum-based therapy in the presence of known BRCA mutation, but later agreed that such therapy should not be routinely used for patients without BRCA mutation.)

**neoadjuvant endocrine therapies**

The Panel was strongly of the opinion that neoadjuvant endocrine therapy without cytotoxics was a reasonable option for postmenopausal patients with endocrine responsive disease. Indeed, the Panel considered that the preferred treatment of postmenopausal women with 'luminal A-like' breast cancer not suitable for breast-conserving surgery at diagnosis was endocrine rather than cytotoxic neoadjuvant therapy. The Panel considered that such treatment should continue for either 4–8 months or until maximal response.

**bisphosphonates**

The Panel was divided about the use of bisphosphonates such as zoledronic acid or clodronate to improve disease-free survival. In postmenopausal patients, a slim majority would support such treatment. Only a minority would support such treatment in premenopausal patients receiving LHRH and tamoxifen. The Panel was virtually unanimous in rejecting such treatment of premenopausal patients not receiving LHRH and would not support the use of denosumab as a substitute for bisphosphonates.

**elderly patients**

The Panel considered that there was no absolute age limit for the use of standard chemotherapy regimens. Rather, the use of such treatments should depend on disease characteristics, comorbidity, life expectancy, and patient preference.

Similarly, the Panel considered that there was no age at which radiation therapy otherwise indicated should be omitted.

**young patients**

The Panel considered that testing for BRCA 1 and BRCA 2 mutations is indicated in patients aged <40 years and those with a strong family history, but was divided about whether this should be extended to testing for high-risk mutations in other genes. The Panel would extend testing to patients up to the age of 50 with triple-negative disease even in the absence of a family history.

The Panel considered that fertility preservation by ovarian tissue or oocyte conservation should be offered upon request for patients aged <40.

The Panel strongly supported the use of OFS during chemotherapy for receptor-negative disease to preserve ovarian function and fertility.

**high-risk mutations**

The presence of a BRCA 1 or BRCA 2 mutation was thought to influence locoregional and neoadjuvant treatment, but not adjuvant therapy.

**breast cancer diagnosed during pregnancy**

For patients whose breast cancer was diagnosed during pregnancy premature delivery should be avoided if possible, and standard chemotherapy regimens should be offered during the third or second trimester, but not anti-HER-2 or endocrine therapies. The Panel considered that breast conservation was a suitable option; that sentinel node biopsy using radioisotopes was safe; and that immediate post mastectomy reconstruction could be considered.

**attempting pregnancy after breast cancer**

The Panel acknowledged the possibility of interrupting endocrine therapy after 18–30 months to allow attempted pregnancy, but only in the absence of high-risk features.

**male breast cancer**

Recognizing that the current adjuvant treatment of males with breast cancer is tamoxifen, the Panel did not support the use of AIs, either with or without LHRH agonists.

**lifestyle factors to reduce the risk of recurrence**

The Panel supported the use of an exercise regimen and weight loss (or at least avoidance of weight gain). They did not recommend any specific dietary advice to improve prognosis, but a majority would support vitamin D supplementation for those shown to be vitamin D deficient.
**summary of treatment recommendations**

**surgery**

Meta-analysis of surgical series showed no further benefit from margins beyond ‘no ink on invasive tumor or DCIS’, including patients with lobular histology, extensive intraductal component, young age, or unfavorable biological subtype.

Axillary dissection can be avoided for patients with one or two macrometastatic lymph nodes.

**radiotherapy**

Disease control and survival are improved when radiation fields were extended to include regional lymph node areas in patients with node-positive disease.

**neoadjuvant systemic therapies**

While acknowledging that neoadjuvant therapy has not been shown to produce survival outcomes superior to those of postoperative adjuvant therapy alone, there is increasing support for neoadjuvant cytotoxic therapy in Stage II triple-negative disease and for combined chemotherapy and anti-HER2 therapy in patients with HER2-positive disease and large tumors. In patients with luminal disease, there is less indication for neoadjuvant cytotoxic chemotherapy unless it is given to enable breast conservation, but the option of neoadjuvant endocrine therapy also exists for many of these patients.

**postoperative systemic adjuvant therapies**

As summarized in Tables 2 and 3, most patients with triple-negative disease should receive cytotoxic chemotherapy containing an anthracycline and a taxane, though a slim majority of the Panel felt that platinum-based therapy might be considered for a patient with known BRCA mutation.

In patients with HER2-positive, node-negative disease and T-size <2 cm, a nonanthracycline regimen comprising paclitaxel and 1 year of trastuzumab is appropriate, while for more extensive disease treatment should commence with anthracycline and be followed by concurrent taxane and trastuzumab, with the trastuzumab continued for a total of 1 year.

Patients with hormone receptor-positive and HER2-positive disease will require endocrine therapy appropriate to their menopausal status in addition to cytotoxics and anti-HER2 therapy.

For patients with hormone receptor-positive and HER2-negative disease, a spectrum exists in degree of risk and of responsiveness to cytotoxic chemotherapy. Those at lower risk with strongly positive receptors can be adequately treated with endocrine therapy alone. Consideration of the relative level of hormone receptor expression and proliferation are important to determine prognosis and the need for adjuvant chemotherapy. The multiparameter assays, either immunohistochemically based ‘IHC4’ as carried out by Cuzick and Dowsett or one of several multiparameter molecular marker assays, such as OncotypeDx®, MammaPrint®, Endopredict®, PAM50 ROR®, and BCIP®, each appears to identify a group of patients for whom prognosis is so favorable that even if chemotherapy is effective, the benefits of treatment are so small that they do not outweigh the risks. For patients with worse anatomical prognostic features, such as the presence of a T4 lesion, high Ki-67, low hormone receptor staining or four or more positive axillary lymph nodes, even those with favorable multiparameter molecular assay results may have a sufficiently high risk of recurrence to justify adjuvant chemotherapy.

Endocrine therapy for premenopausal patients at low risk should comprise tamoxifen for 5 years, while those at higher risk should be considered for OFS and the substitution of exemestane for tamoxifen. In patients who have completed 5 years of adjuvant tamoxifen therapy and are regarded as being at higher risk, it is appropriate to consider continuing endocrine treatment with aromatase inhibitors.

---

**Table 2. Treatment-oriented classification of subgroups of breast cancer**

| Clinical grouping | Notes |
|-------------------|-------|
| **Triple-negative** | Negative ER, PgR, and HER2 |
| Hormone receptor-negative and HER2-positive | ASCO/CAP guidelines |
| Hormone receptor-positive and HER2-positive | ASCO/CAP guidelines |
| Hormone receptor-positive and HER2-negative luminal disease as a spectrum: | ER and/or PgR positive ≥1%<sup>a</sup> |
| High receptor, low proliferation, low tumor burden (luminal A-like) | Multiparameter molecular marker ‘favorable prognosis’ if available. High ER/PgR and clearly low Ki-67<sup>b</sup>. Low or absent nodal involvement (N 0–3), smaller T size (T1 T2). |
| Intermediate | Multiparameter molecular marker ‘intermediate’ if available<sup>c</sup>. Uncertainty persists about degree of risk and responsiveness to endocrine and cytotoxic therapies. |
| Low receptor, high proliferation, high tumor burden (luminal B-like) | Multiparameter molecular marker ‘unfavorable prognosis’ if available. Lower ER/PgR with clearly high Ki-67<sup>b</sup>. More extensive nodal involvement, histological grade 3, extensive lymphovascular invasion, larger T size (T3). |

<sup>a</sup>ER values between 1% and 9% were considered equivocal. Thus, endocrine therapy alone cannot be relied upon for patients with these values.

<sup>b</sup>Ki-67 scores should be interpreted in the light of local laboratory values: as an example, if a laboratory has a median Ki-67 score in receptor-positive disease of 20%, values of 30% or above could be considered clearly high; those of 10% or less clearly low.

<sup>c</sup>Not all multiparameter molecular marker tests report an intermediate score.
For patients postmenopausal at presentation, tamoxifen alone may be suitable for those at lower risk while, for other patients, an AI should be considered and given up front, especially in those at higher risk. Many patients now receive an AI for all or part of their first 5 years of endocrine therapy. While there is less evidence to guide extended endocrine therapy in such patients, continuation of an AI to a cumulative exposure of 5 years seems appropriate. There is no evidence on the safety or efficacy of longer periods of AI therapy, but studies of such treatment are in progress.

**Acknowledgements**

We gratefully acknowledge all participants in the 14th St Gallen conference for their many useful suggestions. In addition to Panel members, we thank Sabina Briner, Carmen Criscitiello, and Shari Gelber for their substantial assistance in the preparation of this report.

**Funding**

Support for the conference was provided by the Educative Foundation, St Gallen Oncology Conferences (SONK) from registration fees paid by the conference attendees; by Grant No. CA75362 from the United States National Cancer Institute (IBCSG Statistical Center, M. Regan, PI) and by Susan G. Komen* (grant No SPP150019).

**References**

1. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v 1.0, Cancer Incidence and Mortality Worldwide. 2013. Lyon, International Agency for Research on Cancer. IARC CancerBase No. 11.
2. Coates AS. Evolution of the St. Gallen Consensus process for the optimal treatment of women with breast cancer. Breast 2015; 24(Suppl 1): PG 0.1.
3. Pagani O, Regan MM, Walley BA et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107–118.
4. Francis PA, Regan MM, Fleming GF et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372: 436–446.
5. Moore HG, Unger JM, Phillips KA et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015; 372: 923–932.
6. Dengel LT, Van Zee KJ, King TA et al. Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Ann Surg Oncol 2014; 21: 22–27.
7. Moran MS, Schnitt SJ, Giuliano AE et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-

---

### Table 3. Postoperative adjuvant systemic treatment recommendations

| Clinical grouping | Type of therapy | Notes on therapy |
|-------------------|-----------------|------------------|
| Triple-negative    | Cytotoxic chemotherapy including anthracycline and taxane | Platinum-based chemotherapy may be considered in patients with known BRCA mutation, see text |
| ER negative and HER2-positive | | |
| T1a node negative | No systemic therapy | |
| T1 b,c node negative | Chemotherapy plus trastuzumab | Consider paclitaxel plus 12 months trastuzumab without anthracycline |
| Higher T or N stage | Anthracycline → taxane with concurrent trastuzumab continued to 12 months | Patients unsuitable for anthracycline may be treated with TCH regimen, though cardiac contraindications to anthracycline may also argue against trastuzumab [115] |
| ER positive and HER2-positive | As above plus endocrine therapy appropriate to menopausal status as below | |
| ER positive and HER2-negative (luminal disease) | Endocrine therapy alone according to menopausal status | See Table 2. Consider chemotherapy if four or more nodes involved |
| Without markers of less endocrine responsiveness (luminal A-like) | | |
| Premenopausal low risk | Tamoxifen 5 years | See criteria in papers [3, 4, 116] |
| Premenopausal other | Tamoxifen 5–10 years or OFS plus tamoxifen or OFS plus exemestane | |
| Postmenopausal low risk | Tamoxifen 5 years | No evidence on the safety or efficacy of more than 5 years of an AI |
| Postmenopausal other | AI preferably up front; extended adjuvant therapy (see text) | |
| With markers suggesting lesser endocrine responsiveness (luminal B-like) | Endocrine therapy as above plus adjuvant cytotoxic chemotherapy in many cases | See Table 2 |
| Factors supporting omission of cytotoxic chemotherapy despite ‘luminal B-like’ phenotype | ‘good’ result of multiparameter molecular test if available | |
12. Haviland JS, Owen JR, Dewar JA et al. The UK Standardisation of Breast radiation therapy for breast cancer. N Engl J Med 2010; 362: 513–520.

17. Dowsett M, Sestak I, Lopez-Knowles E et al. Comparison of PAM50 risk of recurrence score with oncotype DX and iHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013; 31: 2783–2790.

18. Eiermann W, Rezai M, Kummel S et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol 2013; 24: 618–624.

19. Prat A, Cheang MC, Martin M et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013; 31: 203–209.

20. Nielsen TO, Parker JS, Leong S et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 5222–5232.

21. Coates AS, Miller Ek, O'Toole SA et al. Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from BCSS Trials VIII and IX. Breast Cancer Res 2012; 14: R143.

22. Regan MM, Pagani O, Walley B et al. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol 2008; 19: 1231–1241.

23. Wippati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.

24. de Azambuja E, Cardoso F, de Castro G, Jr et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer 2007; 96: 1504–1513.

25. Cricciello C, Disalvatore D, De Laurentiis M et al. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. Breast 2014; 23: 69–75.

26. Denkert C, von Minckwitz G. Reply to Ki67 in breast cancer: a useful prognostic marker? Ann Oncol 2014; 25: 542–543.

27. Polley MY, Leung SC, McShane LM et al. An international Ki67 reproducibility study. J Natl Cancer Inst 2013; 105: 1897–1906.

28. Bouganim N, Tsvetkova E, Cremons M et al. Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Res Treat 2013; 139: 603–606.

29. Houssami N, Moroz M. Margins in breast conservation: a clinician’s perspective and what the literature tells us. J Surg Oncol 2014; 110: 2–7.

30. Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011; 305: 569–575.

31. Donker M, van Tienhoven G, Straver ME et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15: 1303–1310.

32. Wolmark N, Mamounas EP, Batheh FL et al. Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen. J Clin Oncol 2014; 32(Suppl): abstr 11024.

33. Nielsen T, Wilden I, Schaper C et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer 2014; 14: 177.

34. Sestak I, Cuzick J, Dowsett M et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian Breast and Colorectal Cancer Study Group B and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. J Clin Oncol 2015; 33: 916–922.

35. Sestak I, Dowsett M, Zabaglo L et al. Factors predicting late recurrence–estrogen receptor-positive breast cancer. J Natl Cancer Inst Monogr 2013; 105: 1504–1511.

36. Dubsky P, Brase JC, Jakes R et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer 2013; 109: 2959–2964.

37. Zhang Y, Schnabel CA, Schroeder BE et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res 2013; 19: 4196–4205.

38. Del Mastro L, Boni L, Michieli A et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer. JAMA 2011; 306: 269–276.

39. Gerber B, von Minckwitz MG, Stehle H et al. Effect of lutetium-nanoparticle-hormone releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011; 29: 2334–2341.

40. Sledge GW, Hudis CA, Swain SM et al. ASCO’s approach to a learning health care system in oncology. J Oncol Pract 2013; 9: 145–148.

41. Campbell P. Interpreting genomics data at a functional level: what are we learning from large molecular screening projects? Breast 2015; 24(Suppl 1): PG 2.01.

42. Viale G, Slaats L, Bogaerts J et al. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint®) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Ann Oncol 2014; 25: 816–823.

43. Reis-Filho J, Weigelt B. Disparities between genetic tools and immunohistochemistry: bad pathology and good signature, and vice-versa. Breast 2015; 24(Suppl 1): PG 2.03.

44. Maisonneuve P, Disalvatore D, Rotmensz N et al. Proposed new criteria to distinguish luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res 2014; 16: R65.

45. Viale G. A bad tumor biomarker is as bad as a bad drug: the gap between genetics data and phenotype to predict response. Breast 2015; 24(Suppl 1): PG 2.04.

46. Prat A, Blanchini G, Thomas M et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAA study. Clin Cancer Res 2014; 20: 511–521.

47. Schneeweiss A, Chia S, Hickish T et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHENA). Ann Oncol 2013; 24: 2278–2284.

48. Schneeweiss A, Chia S, Hogg R et al. Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-
based therapy: an exploratory analysis of the TRYPHAENA study. Breast Cancer Res 2014; 16: R73.

49. Pratt A, Adamo B, Cheang MC et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013; 18: 123–133.

50. Loibl S. Primary systemic therapy for clinicians: medical and research perspectives. Breast 2015; 24(Suppl 1): PG 8.01.

51. Masuda H, Baggerly KA, Wang Y et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013; 19: 5533–5540.

52. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750–2767.

53. Adams S, Gray RJ, Demaria S et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32: 2959–2966.

54. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25: 1544–1550.

55. Perez EA, Ballman KV, Anderson SK et al. Stromal tumor-infiltrating lymphocytes (S-TILs): in the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit. Cancer Res 2015; 75: abstr S1-06.

56. Milgate CS, Goinathan G, Evrett G et al. Adaptive upregulation of EGF limits attenuation of tumor growth by neutralizing IL6 antibodies, with implications for combined therapy in ovarian cancer. Cancer Res 2015; 75: 1255–1264.

57. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PO-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563–567.

58. Curigliano G. Immune pathways and immunoevasion as a target. Breast 2015; 24 (Suppl 1), PG 4.02.

59. Nanda R, Chow LD, Deos EC et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res Suppl 2015(Suppl): S1-09.

60. Finn RS, Crown JP, Lang I et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment for postmenopausal oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/1RHO-18): a randomised phase 2 study. Lancet Oncol 2015; 16: 25–35.

61. Telli ML, Jensen KC, Vinagak S et al. Phase II study of gemcitabine, carboplatin, and infiribin as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PEGO G 0105. J Clin Oncol 2015 Apr 6 [pub ahead of print], pii: JCO.2014.57.0085.

62. von Minckwitz G, Hahnen E, Fasching PA et al. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSirotx. J Clin Oncol 2014; 32(5a): abstr 1005.

63. Tutt A, Ellis P, Kilburn LS et al. TNT: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer CRUK/07/012. Cancer Res Suppl 2014; 75: S3-01.

64. Bazela J. Targeting PIK3CA pathway. Breast 2015; 24(Suppl 1): PG 5.03.

65. Andre F, Bachelot T, Campone M et al. Targeting FGFR with dovitinib (TKI258): clinical and clinical data in breast cancer. Clin Cancer Res 2013; 19: 3693–3702.

66. Soria JC, DeBraud F, Bahleda R et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lxicabrutinib in advanced solid tumors. Ann Oncol 2014; 25: 2244–2251.

67. Phillips KA, Milne RL, Rookus MA et al. Tannoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2013; 31: 3091–3099.

68. Hartmann LC, Degnim AC, Santen RJ et al. Abpical hyperplasia of the breast—risk assessment and management options. N Engl J Med 2015; 372: 78–89.

69. Yi M, Luo L, Koenig KB et al. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol 2014; 25: 1004–1011.
108. Wolff AC, Blackford AL, Visvanathan K et al. Risk of marrow neoplasms after
107. Shulman LN, Cirrincione CT, Berry DA et al. Six cycles of doxorubicin and
106. Goodwin PJ. Obesity and insulin resistance: clinical relevance and research
109. Eckhoff L, Knoop A, Jensen MB et al. Persistence of docetaxel-induced
neuropathy and impact on quality of life among breast cancer survivors. Eur J
Cancer 2015; 51: 292–300.
105. Viale G, Regan MM, Dell Orto P et al. Which patients benefit most from adjuvant
endocrine therapy? Breast 2015; 24(Suppl 1): #557.
104. Regan M. Predicting benefit of endocrine therapy. Breast 2015; 24(Suppl 1):
PG 11.03.
103. Bernhard J, Luo W, Ribi K et al. Patient-reported endocrine symptoms, sexual
functioning, and quality of life (QoL) in the BCSS TEXT and SOFT trials: adjuvant
treatment with exemestane (E) plus ovarian function suppression (OFS) versus
tamoxifen (T) plus ovarian function suppression (OFS) in premenopausal women
with hormone receptor-positive (HR+) early breast cancer (BC). J Clin Oncol 2015;
32(Suppl 15): #557.
102. Ribi K, Luo W, Francis P et al. Patient-reported endocrine symptoms, sexual
functioning and quality of life (QoL) in the BCSS SOFT trial: adjuvant treatment
with tamoxifen (T) alone versus T plus ovarian function suppression (OFS) in
premenopausal women with hormone receptor-positive (HR+) early breast cancer
(BC). Cancer Res Suppl 2014; S3-09.
101. Tsvaeranek AJ, Wang M, Zhao F et al. Phase III comparison of tamoxifen versus
the Eastern Cooperative Oncology Group. J Clin Oncol 2014; 32: 3948–3958.
100. Grant M, Milnertsch B, Stoeger H et al. Zoledronic acid combined with adjuvant
docrine therapy of tamoxifen versus anastrozole plus ovarian function suppression
in premenopausal early breast cancer: final analysis of the Austrian Breast and
Cancerous Study Group Trial 12. Ann Oncol 2015; 26: 313–320.
99. Thorsen LB, Thomsen MS, Berg M et al. CT-planned internal mammary node
radiotherapy in the DBCG-IMN study: benefits versus potentially harmful effects.
Acta Oncol 2014; 53: 1027–1034.
98. Ataseven B, Lederer B, Blohmer JU et al. Impact of multifocal or multicentric
disease on surgery and locoregional, distant and overall survival of 6,134 breast
cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol 2015;
22: 1118–1127.
97. Yamold J. Hypofractionated radiotherapy in early breast cancer: clinical,
dosimetric and radio-genomic issues. Breast 2015; 24(Suppl 1): PG 10.01.
96. Viale G, Regan MM, Dell Orto P et al. The National Comprehensive Cancer
Network input to the discussion and manuscript.
95. Galimberti V. Feasibility of sentinel node biopsy in breast cancer after neoadjuvant
therapy. Breast 2015; 22: 1118–127.
94. Bogghej JC, Suman VJ, Mittendorf EA et al. Factors affecting sentinel lymph
node identification rate after neoadjuvant chemotherapy for breast cancer
patients enrolled in ACOSOG Z1071 (Alliance), Ann Surg 2015; 261: 547–552.
93. Boileau JF, Poirier B, Baïsk M et al. Sentinel node biopsy after neoadjuvant
chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC Study.
J Clin Oncol 2015; 33: 258–264.
92. Kuehn T, Bauerfeind I, Fehm T et al. Sentinel-lymph-node biopsy in patients with
breast cancer before and after neoadjuvant chemotherapy (SENTINA): a
prospective, multicentre cohort study. Lancet Oncol 2013; 14: 609–618.
91. Frangova LV, Molina C, Lipton A et al. The effects of taxanes on bone turnover:
results from a herceptin adjuvant trial. J Clin Oncol 2015; 33: 2582–2598.
90. Guth U, Myrick ME, Viehl CT et al. Increasing rates of contralateral prophylactic
mastectomy—a trend made in USA? Eur J Surg Oncol 2012; 38: 296–301.
89. Partridge AH, Gelber S, Piccart-Gebhart MJ et al. Effect of age on breast cancer
outcomes in women with human epidermal growth factor receptor 2-positive
breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 2013; 31:
2692–2698.
88. Tollaney SM, Barry WT, Dang CT et al. Adjuvant paclitaxel and trastuzumab for
node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372:
134–141.
87. Pagani D, Ruggeri M, Maru nata S et al. Pregnancy after breast cancer: are young
patients willing to participate in clinical studies? Breast 2015; 24: 201–207.
86. Early Breast Cancer Trialists’ Collaborative Group. Comparisons between different
polychemotherapy regimens for early breast cancer: meta-analyses of long-term
outcome in 100,000 randomised women in 123 randomised trials. Lancet 2012;
379: 432–444.
85. Hart CO, Di Leo A. Defining optimal duration and predicting benefit from
chemotherapy in patients with luminal-like subtypes. Breast 2015; 24(Suppl 1):
PG 12.02.
84. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive
breast cancer. N Engl J Med 2011; 365: 1273–1283.
83. Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant
tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen
receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381:
805–816.

appendix

Members of the Panel are listed below. All had a significant input to the discussion and manuscript.

- Fabrice André, Research Director, Department of Medical Oncology, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
- José Baselga, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, USA
- Jonas Bergh, Radiumhemmet & Karolinska Oncology, Karolinska Institutet and University Hospital, 171 76, Stockholm, Sweden
- Hervé Bonnefoi, Institut Bergonié Cancer Center, Université de Bordeaux, Bordeaux, France
- Harold Burstein, Department of Medical Oncology/Solid Tumor Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
- Fatima Cardoso, Director Breast Unit, Champalimaud Cancer Center, Avenida Brasilia, 1400-038 Lisbon, Portugal
- Monica Castiglione-Gertsch, International Breast Cancer Study Group, Effingerstrasse 40, 3008 Bern, Switzerland
- Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, 40 Cook Road, Centennial Park NSW 2021, Australia
- Marco Colleoni, Research Unit Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
- Giuseppe Curigliano, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
- Nancy E. Davidson, University of Pittsburgh Cancer Institute and UPMC Cancer Center, 5th Floor, Suite 500, Pittsburgh, PA 15232, USA
- Angelo Di Leo, ‘Sandro Pitigliani’ Medical Oncology Unit, Department of Oncology, Hospital of Prato, Piazza dell’Ospedale, 59100 Prato, Italy
- Bent Ejertsen, Department of Oncology, Bldg 426 Rigshospitalet, Blegdamsvej, 2100 Copenhagen, Denmark
• John F. Forbes, Department of Surgical Oncology, University of Newcastle, Calvary Mater Hospital, ANZ BCTG, Edith Street Waratah, Newcastle 2298 NSW Australia
• Viviana Galimberti, Unit of Molecular Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
• Richard D. Gelber, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
• Michael Gnant, Medical University of Vienna, Department of Surgery and Comprehensive Cancer Center, Währinger Gürtel 18-20, 1090 Wien, Austria
• Aron Goldhirsch, International Breast Cancer Study Group, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy, and Ospedale Italiano, 6962 Viganello-Lugano, Switzerland (Chairman)
• Pamela Goodwin, Department of Medicine, Division of Clinical Epidemiology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital and Princess Margaret Hospital, University of Toronto, 1284-600 University Avenue, Toronto, ON M5G 1X4, Canada
• Nadia Harbeck, Brustzentrum der Universität München, Frauenkliniken Maistragasse-Innenstadt und Großhadern, Marchioninistrasse 15, 81377 München, Germany
• Daniel F. Hayes, Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5942, USA
• Jens Huober, University of Ulm, Department of Gynecology, Comprehensive Cancer Center Ulm, Prittwitzstrasse 43, 89073 Ulm, Germany
• Clifford A. Hudis, Breast Medicine Service, Memorial Sloan-Kettering Cancer Center, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, and Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA
• James N. Ingle, Division of Medical Oncology, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905, USA
• Jacek Jassem, Medical University of Gdansk, Department of Oncology & Radiotherapy, Debinki Street 7, 80-211 Gdansk, Poland
• Zefei Jiang, Breast Cancer Department, Cancer Center of Academy of Military Medical Sciences, 8 Fengtai East Avenue, 100071 Beijing, China
• Per Karlsson, Department of Oncology, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden
• Monica Morrow, Memorial Sloan-Kettering Cancer Center, Evelyn Lauder Breast Center, 300 East 66 Street, New York, NY 10065, USA
• Roberto Orecchia, Scientific Director, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
• C. Kent Osborne, Director, Dan L. Duncan Cancer Center, Baylor College of Medicine, 450A, One Baylor Plaza, Houston, TX 77030, USA
• Ann H. Partridge, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
• Lorena de la Peña, Scientific Director SOLTI, Diputación 256, 4º 1ª, 08007 Barcelona, Spain
• Martine J. Piccart-Gebhart, Internal Medicine, Oncology, Institut Jules Bordet, Rue Héger-Bordet 1, 1000 Brussels, Belgium
• Kathleen I. Pritchard, University of Toronto, Sunnybrook Odette Cancer Centre, Ontario Clinical Oncology Group (OCOG), 2075 Bayview Avenue, Toronto, ON M4N 1H6, Canada
• Emiel J.T. Rutgers, Department of Surgery, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
• Felix Sedlmayer, Department of Radiotherapy and Radiation Oncology, LKH Salzburg, University Clinics, Paracelsus Medical University, Mueeller Haupstr. 48, Salzburg, Austria
• Vladimir Semiglazov, N.N. Petrov Research Institute of Oncology, 68 Leningradskaya Street, Peshchany-2, 197758 St Petersburg, Russia
• Zhi-Ming Shao, Fudan University, Cancer Hospital, 270 Dong-An Road, Shanghai, China
• Ian Smith, Breast Unit, Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London, SW3 6JJ, UK
• Beat Thürlimann, Breast Center, Kantonsspital St Gallen, Rorschacherstrasse 95, 9007 St Gallen, Switzerland
• Masakazu Toi, Department of Breast Surgery, Kyoto University Hospital, 54 Shogoin-Kawahara cho, Sakyo-ku, Kyoto 606-8507, Japan
• Andrew Tutt, Breast Oncology Unit, King’s Health Partners AHSC, Guy’s Hospital, 3rd Floor, Bermondsey Wing, and Institute of Cancer Research London, UK
• Giuseppe Viale, Department of Pathology, European Institute of Oncology and University of Milan, Via Ripamonti 435, 20141 Milan, Italy
• Gunter von Minckwitz, GBG Forschungs GmbH, Martin Behaim Strasse 12, 63263 Neu-Isenburg, Germany
• Toru Watanabe, Department of Medicine, Hamamatsu Oncology Center, Chuo 3-chrome 6-13, Nakaku, Hamamatsu 430-0929, Japan
• Timothy Whelan, Department of Oncology, McMaster University and Juravinski Cancer Centre at Hamilton Health Sciences, 699 Concession Street, Hamilton, ON, L8V 5C2, Canada
• Eric P. Winer, Breast Oncology Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02115, USA (Chairman)
• Binghe Xu, Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China